5237 |
Minimizing Embolic Events: Latest TAVR Data |
Eberhard Grube |
Apr. 12. 21 |
5236 |
Escalation and De-Escalation Strategy for CHIP-PCI Patients: The Temporal Tuning in the TAILORED-CHIP Trial |
Duk-Woo Park |
Apr. 12. 21 |
5235 |
Short DAPT Followed by P2Y12 Monotherapy: New Trend Updates with Clinical Evidences |
Davide Capodanno |
Apr. 12. 21 |
5234 |
Tailored Antithrombotic Strategy for CHIP and HBR Patients - How To Do? |
Philip M. Urban |
Apr. 12. 21 |
5233 |
Evolving Antithrombotic Strategies for Patients with DM and CAD |
Dominick J. Angiolillo |
Apr. 12. 21 |
5232 |
Shorter DAPT vs. Longer DAPT: Whom and How? - Clinician\'s and Trialist\'s Perspective |
Robert W. Yeh |
Apr. 12. 21 |
5231 |
Imaging-Based Treatment of Calcified Coronary Artery |
Takashi Akasaka |
Apr. 12. 21 |
5230 |
How I Adopted Intravascular Imaging into My Cathlab Practice? |
Sunil Rao |
Apr. 12. 21 |
5229 |
iFR vs. FFR in Severe AS Patients: Which Is Better? Is It Valid? |
Nils Johnson |
Apr. 12. 21 |
5228 |
Physiological Assessment of Non-obstructive Coronary Disease (INOCA) |
Javier Escaned |
Apr. 12. 21 |